Yaojie Shi

Cancer Center And State Key Laboratory Of Biotherapy
Chengdu, 610041, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer.

Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer.

Journal: European journal of medicinal chemistry

Published: May 24, 2023

Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives.

Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives.

Journal: Journal of medicinal chemistry

Published: March 20, 2023

Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer.

Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer.

Journal: European journal of medicinal chemistry

Published: August 25, 2021

Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives.

Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives.

Journal: European journal of medicinal chemistry

Published: April 30, 2021

Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitis.

Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitis.

Journal: European journal of medicinal chemistry

Published: April 22, 2019

Corrigendum: Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer.

Corrigendum: Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer.

Journal: Scientific reports

Published: April 30, 2016

Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis.

Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis.

Journal: Scientific reports

Published: March 17, 2016

Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents.

Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents.

Journal: Bioorganic & medicinal chemistry letters

Published: January 07, 2016

A novel small-molecule YLT256 inhibits proliferation and induces apoptosis both in vitro and in vivo in solid tumors.

A novel small-molecule YLT256 inhibits proliferation and induces apoptosis both in vitro and in vivo in solid tumors.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 31, 2015

Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.

Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.

Journal: Scientific reports

Published: November 02, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026